Track record · closed signal

Hims & Hers Health, Inc. (HIMS) — closed signal from December 21, 2025

Partial Published before the outcome was known, scored automatically when the window closed on March 21, 2026.

Predicted vs. what happened

HIMS price · publication thesis → realized outcomesplit-adjusted
$35.56 Published $42.67 Target $22.02 Window close $36.45 Peak
$34.00 – $36.50Entry zone — fair-value band
$35.56Published — price the day we called it
$42.67Target — the price the thesis aimed for
$36.45Peak — highest point inside the window, not a realized return
$22.02Window close — end-of-window price, context only

What happened

Partial

Reached 13% of the predicted growth at its peak, without hitting the target.

Peak price
$36.45
peak on January 7, 2026 — not a realized return
Peak gain
+2.5%
peak, from the publication price
Window close
$22.02
end-of-window price, context only
Days to target
—
Window
December 21, 2025 – March 21, 2026

The thesis — published December 21, 2025

Predicted growth
+20%
over the measurement window
Target price
$42.67
the price the thesis aimed for
Entry zone
$34.00 – $36.50
the fair-value band we waited for
Price at publication
$35.56
published December 21, 2025
Confidence
62%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Hims & Hers is a volatile healthcare growth stock that looks oversold but is showing signs of improving buying interest. A recent $200M+ expansion in Ohio and fast sales growth have put the company back in focus. Analysts see a chance of a rebound, but company results are behind the optimistic market mood, so expect price swings and use smaller positions.

Primary drivers

  • Ohio expansion brings new customers and attention to the story
  • Stock looks oversold but is showing improving buying interest
  • Subscriptions can lift sales quickly if customers convert
  • Use strict position sizing because sentiment outpaces fundamentals

How it played out

HIMS: the target was not reached

Lyra published HIMS at $35.56 on 2025-12-21 with a short-term thesis for 20% expected growth. The target was $42.67. The thesis pointed to a $200M+ Ohio expansion, an oversold setup with improving buying interest, subscription upside if customers converted, and the need for strict position sizing because sentiment was ahead of fundamentals.

Inside the window, HIMS peaked at $36.45 on 2026-01-07, a 2.5% gain. It stayed below the target. By 2026-03-21, it ended at $22.02. The rebound thesis did not play out.

What happened during the window

On 2026-02-19, Hims & Hers agreed to acquire Eucalyptus in a $1.15 billion deal. The article said the deal included $240 million in cash at closing and was expected to close in mid-2026.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HIMS signals